For the year ending 2025-12-31, INTI had -$3,231,370 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -3,300,337 |
| Stock-based compensation | 23,385 |
| Non-cash lease expense | 792 |
| Prepaid expense and other assets | -16,288 |
| Accounts payable and other current liabilities | 28,502 |
| Net cash used in operating activities | -3,231,370 |
| Net decrease in cash and cash equivalents | -3,231,370 |
| Cash and cash equivalents at beginning of year | 5,606,863 |
| Cash and cash equivalents at end of year | 2,375,493 |
Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. (INTI)